ArticleBMC medical genomics2025
Exploring the genetic landscape of COVID-19 susceptibility and severity among patients in Türkiye.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne of the most challenging factors for clinicians in managing COVID-19 has been differences in the clinical course. To investigate the parameters associated with severe disease in detail, along with examining known risk factors such as advanced age and comorbidities, understanding personal genetic factors is necessary, as the clinical course may change due to differences in the host genome.
methodsHuman genetic variants reported to be associated with severe disease were genotyped in 68 patients in COVID-19 medical wards and 52 in COVID-19 intensive care units at Hacettepe University Adult Hospital.
resultsThe rs17860115 variant was significantly more prevalent in our cohort than in the European (non-Finish) population, whereas the rs2298659, rs2298661, rs4290734, and rs9271609 variants were significantly less common, which may reflect genetic differentiation, selective pressures, or protective factors within this population. While no significant association was found between variants and disease severity, notably, the ACE2 rs1548474 allele frequency was 38.0% in the ICU group and 22.9% in the non-ICU group (OR = 2.06; 95% CI 1.10–3.90; p = 0.02).
conclusionThese findings emphasize the importance of examining genetic differences both within and across populations when developing new strategies for disease control and public health policies, particularly for infectious diseases such as COVID-19. They also point to the necessity for further research involving larger and more varied populations to validate these associations and to investigate the genetic factors that may drive them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.